Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Oral,Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Stanford University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Thyroid Cancer
Phase 1: Breast Cancer|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT00199862 | N/A |
Active, not recruiting |
Colorectal Cancer |
2027-06-01 |
2023-06-02 |
||
| NCT03647358 | P1 |
Recruiting |
Thyroid Cancer |
2026-08-01 |
2023-06-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| rhTSH | N/A |
Terminated |
Thyroid Cancer |
2018-10-01 |
2020-08-05 |
Primary Endpoints|Treatments |
|
| NCT02947399 | N/A |
Terminated |
Thyroid Cancer |
2018-10-01 |
2020-08-05 |
Primary Endpoints|Treatments |
|
| DIAMONDT | P2 |
Terminated |
Thyroid Cancer |
2016-01-01 |
2025-05-06 |
Primary Completion Date |
|
| BRS0001 | P1 |
Terminated |
Breast Cancer |
2012-12-01 |
2019-03-18 |